Do analysts prefer DH or AIFF?

Definitive Healthcare presently has a consensus price target of $1.88, suggesting a potential upside of 169.63%. Given Definitive Healthcare's stronger consensus rating and higher possible upside, research analysts plainly believe Definitive Healthcare is more favorable than Firefly Neuroscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Definitive Healthcare 4 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 1.75 Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor DH or AIFF?

In the previous week, Definitive Healthcare had 6 more articles in the media than Firefly Neuroscience. MarketBeat recorded 8 mentions for Definitive Healthcare and 2 mentions for Firefly Neuroscience. Firefly Neuroscience's average media sentiment score of 0.99 beat Definitive Healthcare's score of 0.00 indicating that Firefly Neuroscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definitive Healthcare 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Firefly Neuroscience 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AIFF or DRIO?

DarioHealth has a consensus target price of $10.50, indicating a potential upside of 37.08%. Given DarioHealth's stronger consensus rating and higher possible upside, analysts clearly believe DarioHealth is more favorable than Firefly Neuroscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 DarioHealth 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to AIFF or DRIO?

In the previous week, DarioHealth had 1 more articles in the media than Firefly Neuroscience. MarketBeat recorded 3 mentions for DarioHealth and 2 mentions for Firefly Neuroscience. Firefly Neuroscience's average media sentiment score of 0.99 beat DarioHealth's score of 0.00 indicating that Firefly Neuroscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Firefly Neuroscience 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DarioHealth 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate AIFF or ONMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 OneMedNet 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor AIFF or ONMD?

In the previous week, OneMedNet had 1 more articles in the media than Firefly Neuroscience. MarketBeat recorded 3 mentions for OneMedNet and 2 mentions for Firefly Neuroscience. OneMedNet's average media sentiment score of 1.30 beat Firefly Neuroscience's score of 0.99 indicating that OneMedNet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Firefly Neuroscience 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OneMedNet 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AIFF or ACON?

Aclarion has a consensus price target of $7.50, suggesting a potential upside of 217.80%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than Firefly Neuroscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor AIFF or ACON?

In the previous week, Aclarion had 2 more articles in the media than Firefly Neuroscience. MarketBeat recorded 4 mentions for Aclarion and 2 mentions for Firefly Neuroscience. Firefly Neuroscience's average media sentiment score of 0.99 beat Aclarion's score of -0.40 indicating that Firefly Neuroscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Firefly Neuroscience 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclarion 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ITOC or AIFF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Itonic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, ITOC or AIFF?

Itonic has higher earnings, but lower revenue than Firefly Neuroscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Itonic $520K 9.45 -$5.10M N/A N/A Firefly Neuroscience $1.14M 16.29 -$19.88M -$0.63 N/A

Does the media prefer ITOC or AIFF?

In the previous week, Itonic had 8 more articles in the media than Firefly Neuroscience. MarketBeat recorded 10 mentions for Itonic and 2 mentions for Firefly Neuroscience. Firefly Neuroscience's average media sentiment score of 0.99 beat Itonic's score of 0.06 indicating that Firefly Neuroscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Itonic 0 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Firefly Neuroscience 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Firefly Neuroscience (AIFF) Competitors

$1.19 -0.01 (-0.83%)

As of 04:00 PM Eastern

Compare

AIFF vs. DH, DRIO, ONMD, ACON, and ITOC

Should you buy Firefly Neuroscience stock or one of its competitors? Firefly Neuroscience's main competitors and comparable companies include Definitive Healthcare (DH), DarioHealth (DRIO), OneMedNet (ONMD), Aclarion (ACON), and Itonic (ITOC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Firefly Neuroscience compare to Definitive Healthcare?

Definitive Healthcare (NASDAQ:DH) and Firefly Neuroscience (NASDAQ:AIFF) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Firefly Neuroscience has lower revenue, but higher earnings than Definitive Healthcare. Firefly Neuroscience is trading at a lower price-to-earnings ratio than Definitive Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definitive Healthcare	$241.52M	0.31	-$138.93M	-$1.62	N/A
Firefly Neuroscience	$1.14M	16.29	-$19.88M	-$0.63	N/A

Definitive Healthcare presently has a consensus price target of $1.88, suggesting a potential upside of 169.63%. Given Definitive Healthcare's stronger consensus rating and higher possible upside, research analysts plainly believe Definitive Healthcare is more favorable than Firefly Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definitive Healthcare	4 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	1.75
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

98.7% of Definitive Healthcare shares are owned by institutional investors. Comparatively, 5.0% of Firefly Neuroscience shares are owned by institutional investors. 17.1% of Definitive Healthcare shares are owned by insiders. Comparatively, 6.9% of Firefly Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Definitive Healthcare has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Firefly Neuroscience has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

In the previous week, Definitive Healthcare had 6 more articles in the media than Firefly Neuroscience. MarketBeat recorded 8 mentions for Definitive Healthcare and 2 mentions for Firefly Neuroscience. Firefly Neuroscience's average media sentiment score of 0.99 beat Definitive Healthcare's score of 0.00 indicating that Firefly Neuroscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definitive Healthcare	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Firefly Neuroscience	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Definitive Healthcare has a net margin of -76.04% compared to Firefly Neuroscience's net margin of -565.40%. Definitive Healthcare's return on equity of 4.04% beat Firefly Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definitive Healthcare	-76.04%	4.04%	1.99%
Firefly Neuroscience	-565.40%	-94.68%	-73.51%

Summary

Definitive Healthcare beats Firefly Neuroscience on 12 of the 16 factors compared between the two stocks.

How does Firefly Neuroscience compare to DarioHealth?

Firefly Neuroscience (NASDAQ:AIFF) and DarioHealth (NASDAQ:DRIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

DarioHealth has a consensus target price of $10.50, indicating a potential upside of 37.08%. Given DarioHealth's stronger consensus rating and higher possible upside, analysts clearly believe DarioHealth is more favorable than Firefly Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

5.0% of Firefly Neuroscience shares are owned by institutional investors. Comparatively, 33.4% of DarioHealth shares are owned by institutional investors. 6.9% of Firefly Neuroscience shares are owned by insiders. Comparatively, 3.5% of DarioHealth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Firefly Neuroscience has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, DarioHealth has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Firefly Neuroscience has higher earnings, but lower revenue than DarioHealth. Firefly Neuroscience is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Firefly Neuroscience	$1.14M	16.29	-$19.88M	-$0.63	N/A
DarioHealth	$21.19M	2.65	-$41.71M	-$8.88	N/A

In the previous week, DarioHealth had 1 more articles in the media than Firefly Neuroscience. MarketBeat recorded 3 mentions for DarioHealth and 2 mentions for Firefly Neuroscience. Firefly Neuroscience's average media sentiment score of 0.99 beat DarioHealth's score of 0.00 indicating that Firefly Neuroscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Firefly Neuroscience	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DarioHealth	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DarioHealth has a net margin of -192.23% compared to Firefly Neuroscience's net margin of -565.40%. DarioHealth's return on equity of -60.52% beat Firefly Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Firefly Neuroscience	-565.40%	-94.68%	-73.51%
DarioHealth	-192.23%	-60.52%	-37.08%

Summary

DarioHealth beats Firefly Neuroscience on 11 of the 16 factors compared between the two stocks.

How does Firefly Neuroscience compare to OneMedNet?

Firefly Neuroscience (NASDAQ:AIFF) and OneMedNet (NASDAQ:ONMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

In the previous week, OneMedNet had 1 more articles in the media than Firefly Neuroscience. MarketBeat recorded 3 mentions for OneMedNet and 2 mentions for Firefly Neuroscience. OneMedNet's average media sentiment score of 1.30 beat Firefly Neuroscience's score of 0.99 indicating that OneMedNet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Firefly Neuroscience	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OneMedNet	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Firefly Neuroscience has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market. Comparatively, OneMedNet has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

OneMedNet has a net margin of -254.13% compared to Firefly Neuroscience's net margin of -565.40%. OneMedNet's return on equity of 0.00% beat Firefly Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Firefly Neuroscience	-565.40%	-94.68%	-73.51%
OneMedNet	-254.13%	N/A	-383.90%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
OneMedNet	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

OneMedNet has higher revenue and earnings than Firefly Neuroscience. OneMedNet is trading at a lower price-to-earnings ratio than Firefly Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Firefly Neuroscience	$1.14M	16.29	-$19.88M	-$0.63	N/A
OneMedNet	$1.36M	27.64	-$2.80M	-$0.05	N/A

5.0% of Firefly Neuroscience shares are owned by institutional investors. Comparatively, 1.0% of OneMedNet shares are owned by institutional investors. 6.9% of Firefly Neuroscience shares are owned by company insiders. Comparatively, 46.2% of OneMedNet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

OneMedNet beats Firefly Neuroscience on 10 of the 13 factors compared between the two stocks.

How does Firefly Neuroscience compare to Aclarion?

Firefly Neuroscience (NASDAQ:AIFF) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Aclarion has a consensus price target of $7.50, suggesting a potential upside of 217.80%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than Firefly Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Firefly Neuroscience has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Aclarion has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

In the previous week, Aclarion had 2 more articles in the media than Firefly Neuroscience. MarketBeat recorded 4 mentions for Aclarion and 2 mentions for Firefly Neuroscience. Firefly Neuroscience's average media sentiment score of 0.99 beat Aclarion's score of -0.40 indicating that Firefly Neuroscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Firefly Neuroscience	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclarion	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Firefly Neuroscience has a net margin of -565.40% compared to Aclarion's net margin of -10,948.81%. Aclarion's return on equity of -59.34% beat Firefly Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Firefly Neuroscience	-565.40%	-94.68%	-73.51%
Aclarion	-10,948.81%	-59.34%	-56.12%

5.0% of Firefly Neuroscience shares are held by institutional investors. Comparatively, 7.5% of Aclarion shares are held by institutional investors. 6.9% of Firefly Neuroscience shares are held by insiders. Comparatively, 0.0% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Aclarion has lower revenue, but higher earnings than Firefly Neuroscience. Firefly Neuroscience is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Firefly Neuroscience	$1.14M	16.29	-$19.88M	-$0.63	N/A
Aclarion	$83.77K	69.36	-$7.23M	-$7.40	N/A

Summary

Aclarion beats Firefly Neuroscience on 11 of the 16 factors compared between the two stocks.

How does Firefly Neuroscience compare to Itonic?

Itonic (NASDAQ:ITOC) and Firefly Neuroscience (NASDAQ:AIFF) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

Itonic has a net margin of 0.00% compared to Firefly Neuroscience's net margin of -565.40%. Itonic's return on equity of 0.00% beat Firefly Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Itonic	N/A	N/A	N/A
Firefly Neuroscience	-565.40%	-94.68%	-73.51%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Itonic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

5.0% of Firefly Neuroscience shares are held by institutional investors. 6.9% of Firefly Neuroscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Itonic has a beta of 2.81, indicating that its share price is 181% more volatile than the broader market. Comparatively, Firefly Neuroscience has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

Itonic has higher earnings, but lower revenue than Firefly Neuroscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Itonic	$520K	9.45	-$5.10M	N/A	N/A
Firefly Neuroscience	$1.14M	16.29	-$19.88M	-$0.63	N/A

In the previous week, Itonic had 8 more articles in the media than Firefly Neuroscience. MarketBeat recorded 10 mentions for Itonic and 2 mentions for Firefly Neuroscience. Firefly Neuroscience's average media sentiment score of 0.99 beat Itonic's score of 0.06 indicating that Firefly Neuroscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Itonic	0 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Firefly Neuroscience	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Itonic beats Firefly Neuroscience on 6 of the 11 factors compared between the two stocks.

Get Firefly Neuroscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIFF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIFF vs. The Competition

Export

Metric	Firefly Neuroscience	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.58M	$1.53B	$7.06B	$12.95B
Dividend Yield	N/A	4.71%	2.58%	10.20%
P/E Ratio	-1.89	23.86	269.75	24.73
Price / Sales	16.29	72.44	652.34	108.63
Price / Cash	N/A	30.51	28.89	37.44
Price / Book	2.09	5.35	11.27	6.42
Net Income	-$19.88M	-$25.90M	$3.45B	$347.12M
7 Day Performance	1.71%	7.30%	3.56%	2.48%
1 Month Performance	3.48%	3.09%	-0.58%	-1.04%
1 Year Performance	-58.97%	-16.15%	77.52%	23.22%

Firefly Neuroscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIFF Firefly Neuroscience	0.7565 of 5 stars	$1.19 -0.8%	N/A	-58.6%	$18.58M	$1.14M	N/A	N/A
DH Definitive Healthcare	2.2762 of 5 stars	$0.67 -4.7%	$2.47 +270.3%	-81.5%	$73.87M	$241.52M	N/A	970	News Coverage
DRIO DarioHealth	3.0923 of 5 stars	$7.66 +11.5%	$10.50 +37.1%	-32.4%	$50.44M	$22.36M	N/A	200	Upcoming Earnings Gap Up
ONMD OneMedNet	1.3024 of 5 stars	$0.65 -9.4%	N/A	+32.9%	$40.57M	$1.36M	N/A	2	Positive News Insider Trade Gap Up
ACON Aclarion	3.699 of 5 stars	$2.36 -0.8%	$7.50 +217.8%	-68.1%	$5.86M	$80K	N/A	7	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIFF) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Firefly Neuroscience (AIFF) Competitors

AIFF vs. DH, DRIO, ONMD, ACON, and ITOC

How does Firefly Neuroscience compare to Definitive Healthcare?

Summary

How does Firefly Neuroscience compare to DarioHealth?

Summary

How does Firefly Neuroscience compare to OneMedNet?

Summary

How does Firefly Neuroscience compare to Aclarion?

Summary

How does Firefly Neuroscience compare to Itonic?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIFF vs. The Competition

Firefly Neuroscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Firefly Neuroscience (AIFF) Competitors

AIFF vs. DH, DRIO, ONMD, ACON, and ITOC

How does Firefly Neuroscience compare to Definitive Healthcare?

Which has better valuation & earnings, DH or AIFF?

Do analysts prefer DH or AIFF?

Do institutionals and insiders have more ownership in DH or AIFF?

Which has more volatility and risk, DH or AIFF?

Does the media favor DH or AIFF?

Is DH or AIFF more profitable?

Summary

How does Firefly Neuroscience compare to DarioHealth?

Do analysts recommend AIFF or DRIO?

Do institutionals & insiders believe in AIFF or DRIO?

Which has more volatility and risk, AIFF or DRIO?

Which has preferable valuation and earnings, AIFF or DRIO?

Does the media refer more to AIFF or DRIO?

Is AIFF or DRIO more profitable?

Summary

How does Firefly Neuroscience compare to OneMedNet?

Does the media favor AIFF or ONMD?

Which has more risk and volatility, AIFF or ONMD?

Is AIFF or ONMD more profitable?

Do analysts rate AIFF or ONMD?

Which has stronger earnings and valuation, AIFF or ONMD?

Do insiders & institutionals hold more shares of AIFF or ONMD?

Summary

How does Firefly Neuroscience compare to Aclarion?

Do analysts recommend AIFF or ACON?

Which has more risk and volatility, AIFF or ACON?

Does the media favor AIFF or ACON?

Is AIFF or ACON more profitable?

Do insiders and institutionals hold more shares of AIFF or ACON?

Which has stronger valuation & earnings, AIFF or ACON?

Summary

How does Firefly Neuroscience compare to Itonic?

Is ITOC or AIFF more profitable?

Do analysts recommend ITOC or AIFF?

Do institutionals and insiders have more ownership in ITOC or AIFF?

Which has more risk and volatility, ITOC or AIFF?

Which has higher earnings and valuation, ITOC or AIFF?

Does the media prefer ITOC or AIFF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIFF vs. The Competition

Firefly Neuroscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools